Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation
Researchers investigating incretin-based receptor pharmacology may find the following external resources useful: retatrutide triple-hormone-receptor agonist clinical trial (PMID: 37366315) and NCBI Biotechnology Information
Retatrutide is being researched for obesity, overweight with weight-related health concerns, type 2 diabetes, and other metabolic conditions
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
Many experienced semaglutide users combine two products, often Pendulum plus either Culturelle or Align, to cover both GLP-1 enhancement and symptom-specific relief
Understanding who does what helps you evaluate the platform and know exactly who is responsible for each part of your care
